The TGM2 Knockout HeLa Cell Line is a CRISPR/Cas9-edited knockout cell line engineered to disrupt the TGM2 gene, which encodes transglutaminase 2, a multifunctional calcium-dependent enzyme. This loss-of-function model enables robust investigation of TGM2-dependent cellular processes without relying on transient suppression methods. The knockout cell line is derived from the HeLa parental line and serves as a stable, tractable system for dissecting TGM2-mediated signaling and enzymatic functions in a human epithelial context.
HeLa cells are a classic human cervical adenocarcinoma epithelial line that harbors HPV18 sequences, providing a well-characterized model for studying oncogenic transformation, viral host interactions, and tumor cell biology. Their rapid proliferation, ease of genetic manipulation, and extensive literature background make them a preferred host for gene knockout studies in cancer and cell signaling research. This TGM2-deficient derivative retains the core properties of the parental HeLa line while eliminating endogenous transglutaminase activity, enabling comparative analyses of TGM2-dependent phenotypes.
TGM2 functions as a calcium-dependent transamidase that cross-links extracellular matrix (ECM) proteins such as fibronectin and osteopontin, thereby stabilizing the ECM and modulating integrin-mediated adhesion. Intracellularly, TGM2 operates as a GTP-binding protein and interacts with multiple signaling nodes. It is induced by TNF-alpha, TGF-beta, and hypoxia via HIF-1alpha and activates NF-kappaB signaling by cross-linking I-kappaBalpha, leading to its degradation and release of NFKB1/RELA dimers. Additionally, TGM2 facilitates TGF-beta pathway activation by promoting TGFBR1-mediated phosphorylation of SMAD2/3, and enhances focal adhesion kinase (FAK) and RhoA signaling, linking ECM remodeling to cytoskeletal dynamics and survival. Interactions with beta-catenin further connect TGM2 to Wnt signaling, underscoring its pleiotropic roles in cellular homeostasis and disease.
In the HeLa cervical carcinoma background, loss of TGM2 is expected to attenuate ECM cross-linking and alter adhesion-dependent signaling, providing a powerful model to examine mechanisms of cancer cell migration, invasion, and anoikis resistance. The knockout line allows dissection of how TGM2 integrates signals from the tumor microenvironment??such as TGF-beta and TNF-alpha??to drive oncogenic NF-kappaB and FAK/RhoA pathways. It also offers a platform to study the interplay between HPV oncoproteins and host transglutaminase activity in cervical cancer progression, potentially revealing vulnerabilities for therapeutic intervention.
Researchers can employ this cell line in a variety of assays to interrogate TGM2 function. Transglutaminase activity assays and western blotting confirm protein loss and enzymatic deficiency, while cell adhesion and migration/invasion assays quantify phenotypic changes. Apoptosis assays, such as Annexin V/PI staining, reveal altered survival signaling, and immunofluorescence or RT-qPCR can assess downstream target expression and localization. The model is particularly suited for testing transglutaminase inhibitors, investigating drug resistance mechanisms, and exploring ECM-dependent signaling in cancer metastasis. For technical specifications and ordering information, please contact Ascent Research.
